GlassScriptPhysician profile
Margaret E Sharron
NPI 1477651677
$8,061.03
in general payments reported to CMS, 2019-2025
30 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,246 · 2022: $1,261 · 2023: $1,634 · 2024: $2,272 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,514 · Education: $40.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,513.88 |
| Education | $40.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,454.75 | 2021-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $999.77 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $899.00 | 2021-2025 | |
| Pfizer INC. | $549.13 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $525.82 | 2021-2025 | Dupixent |
| Csl Behring | $505.48 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Amgen INC. | $455.34 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $366.38 | 2022-2025 | Ruconest |
| Genentech USA, INC. | $321.58 | 2022-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $243.13 | 2022-2025 | Takhzyro, Cuvitru, Hyqvia |
| Genzyme Corporation | $241.63 | 2021-2025 | |
| Blueprint Medicines Corporation | $216.14 | 2023-2025 | Ayvakit |
| Abbvie INC. | $215.43 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.58 | 2021-2022 | |
| Novo Nordisk INC | $118.30 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $96.28 | 2023-2025 | Orladeyo |
| Kaleo, INC. | $92.00 | 2021-2023 | Auvi-Q |
| Gc Biopharma USA, INC. | $80.39 | 2025 | Alyglo |
| Grifols USA, LLC | $78.78 | 2021-2025 | Xembify |
| Lilly USA, LLC | $69.91 | 2024-2025 | Ebglyss |
| Cycle Pharmaceuticals INC | $59.33 | 2024-2025 | Sajazir |
| Covis Pharma Gmbh | $58.74 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $55.75 | 2021-2022 | |
| Leo Pharma INC. | $48.19 | 2022-2023 | Adbry |
| Optinose US, INC. | $42.49 | 2022 | |
| Bio Products Laboratory USA, INC. | $33.39 | 2022 | |
| Uswm, LLC | $31.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.85 | 2021 | |
| Horizon Therapeutics Plc | $20.49 | 2023 | Actimmune |
| Organon LLC | $17.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Sharron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.